December 9, 2020 – Thermo Fisher Scientific (Waltham, MA) announced it will further expand its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.
Thermo Fisher is currently expanding its sites in:
- Greenville, NC
- Swindon, U.K.
- Ferentino and Monza, Italy
These investments will add 15 development and cGMP commercial production lines, leveraging Thermo Fisher’s robust quality standards as well as supporting a range of capabilities including live virus, aseptic liquid and lyophilized vial filling. These projects are expected to be completed over the next two years and will create approximately 1,000 jobs, the company says.
In addition to expansions in North America and Europe, the company recently announced significant projects in Asia-Pacific, including a new sterile manufacturing facility in Singapore and a new integrated biologics and sterile drug development and manufacturing site in Hangzhou, China.